MarketCap
Facebook
X
TelegramQuarterly report 2025-Q4
added 02-11-2026
Veru EPS Ratio 2011-2026 | VERU
EPS is a measure used to assess the financial stability and profitability of a company. EPS (Earnings Per Share) represents the company's net income divided by the number of its outstanding shares. This measure allows investors and analysts to evaluate the return on investment in the company's stock and compare it to other companies in the industry.
The term earnings per share (EPS) represents the portion of a company's earnings, net of taxes and preferred stock dividends, that is allocated to each share of common stock. The figure can be calculated simply by dividing net income earned in a given reporting period (usually quarterly or annually) by the total number of shares outstanding during the same term. Because the number of shares outstanding can fluctuate, a weighted average is typically used.
Calculated as:
EPS = (Net Income - Dividends on Preffered Stock) / Average Outstanding shares[1]
EPS can be calculated as a simple ratio of net income to shares, or in various variations, such as diluted EPS, which takes into account the potential issuance of new shares or convertible securities.
A high EPS ratio usually indicates that the company has good profitability and efficiency in utilizing its assets. However, other factors such as sales growth, debt burden, and the company's competitive position should also be considered.
EPS ratio is an important indicator for investors when making decisions to buy or sell a company's stock. It is also used by analysts to assess the financial condition of the company and its potential for growth and development.
Annual EPS Ratio Veru
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -0.28 | -1.1 | -0.48 | 0.1 | -0.28 | -0.19 | -0.44 | -0.25 | 0.01 | 0.15 | 0.09 | 0.51 | 0.55 | 0.2 |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 0.55 | -1.1 | -0.101 |
Quarterly EPS Ratio Veru
| 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -0.26 | - | -0.5 | -0.05 | -0.61 | - | -0.75 | -0.07 | -0.08 | - | -0.14 | -0.42 | -0.48 | -0.53 | -0.28 | -0.18 | -0.08 | 0.16 | -0.03 | -0.04 | 0.25 | -0.11 | -0.05 | 0.25 | -0.05 | -0.14 | -0.04 | -0.06 | -0.03 | -0.3 | -0.15 | -0.03 | -0.08 | -0.12 | -0.03 | -0.06 | -0.04 | -0.06 | 0.02 | -0.04 | 0.05 | 0.02 | 0.04 | 0.05 | 0.03 | -0.02 | 0.04 | 0.03 | 0.05 | 0.23 | 0.03 | 0.05 | 0.12 | 0.26 | 0.09 | 0.12 | 0.1 | 0.03 | 0.02 | 0.1 |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 0.26 | -0.75 | -0.0661 |
References
- Khan, T. R., Islam, M. R., Choudhury, T. T., & Adnan, A. M. (2014). How earning per share (EPS) affects on share price and firm value.
EPS Ratio of other stocks in the Drug manufacturers industry
| Issuer | EPS Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Assertio Holdings
ASRT
|
-4.74 | $ 19.26 | 0.25 % | $ 123 M |  USA |
 |
AcelRx Pharmaceuticals
ACRX
|
-0.34 | - | 7.5 % | $ 6.35 M | USA |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
-0.18 | - | 0.86 % | $ 117 M | USA |
 |
Aerie Pharmaceuticals
AERI
|
-1.61 | - | - | $ 754 M | USA |
 |
Bausch Health Companies
BHC
|
-1.62 | $ 5.39 | 0.56 % | $ 1.97 B |  Canada |
 |
Avadel Pharmaceuticals plc
AVDL
|
-0.51 | - | - | $ 2.06 B |  France |
 |
Canopy Growth Corporation
CGC
|
-5.56 | $ 1.01 | 0.91 % | $ 109 M | Canada |
 |
Cumberland Pharmaceuticals
CPIX
|
-0.14 | $ 3.23 | 1.98 % | $ 45.4 M | USA |
 |
Emergent BioSolutions
EBS
|
-14.8 | $ 8.29 | 0.73 % | $ 424 M | USA |
 |
Catalent
CTLT
|
-5.76 | - | - | $ 11.5 B | USA |
 |
Evolus
EOLS
|
-0.8 | $ 4.2 | 4.09 % | $ 271 M | USA |
 |
Agile Therapeutics
AGRX
|
-6.71 | - | 10.11 % | $ 58.2 M | USA |
 |
Alimera Sciences
ALIM
|
-0.84 | - | - | $ 142 M | USA |
 |
Athenex
ATNX
|
-15.8 | - | -23.39 % | $ 1.76 M | USA |
 |
Eagle Pharmaceuticals
EGRX
|
2.76 | - | -39.89 % | $ 27.7 M | USA |
 |
Harrow Health
HROW
|
-0.14 | $ 35.45 | 0.4 % | $ 1.3 B | USA |
 |
DURECT Corporation
DRRX
|
-1.05 | - | - | $ 50.1 M | USA |
 |
Calliditas Therapeutics AB (publ)
CALT
|
-9.66 | - | -0.1 % | $ 2.03 B |  Schweden |
 |
Evoke Pharma
EVOK
|
-2.33 | - | - | $ 36.6 M | USA |
 |
HEXO Corp.
HEXO
|
-0.89 | - | 2.45 % | $ 38.1 M | Canada |
 |
Endo International plc
ENDP
|
-10.4 | - | - | $ 28.9 M |  Irlanda |
 |
OrganiGram Holdings
OGI
|
-0.51 | $ 1.4 | 1.45 % | $ 402 M | Canada |
 |
Aurora Cannabis
ACB
|
-4.1 | $ 3.49 | 1.45 % | $ 86.3 M | Canada |
 |
Organogenesis Holdings
ORGO
|
-0.01 | $ 2.35 | 4.69 % | $ 309 M | USA |
 |
Pacira BioSciences
PCRX
|
-2.15 | $ 22.39 | -1.37 % | $ 1.04 B | USA |
 |
Relmada Therapeutics
RLMD
|
-1.45 | $ 6.94 | -0.72 % | $ 274 M | USA |
 |
Rockwell Medical
RMTI
|
-0.15 | $ 0.96 | 0.32 % | $ 34.5 M | USA |
 |
SCYNEXIS
SCYX
|
-0.17 | $ 0.93 | 4.52 % | $ 46.4 M | USA |
 |
Sundial Growers
SNDL
|
-1.1 | $ 1.36 | - | $ 3.37 M | Canada |
 |
Solid Biosciences
SLDB
|
-1.99 | $ 8.03 | 7.17 % | $ 703 M | USA |
 |
Sonoma Pharmaceuticals
SNOA
|
-2.79 | $ 2.36 | -0.42 % | $ 2.93 M | USA |
 |
Tilray
TLRY
|
-2.35 | $ 6.83 | 4.27 % | $ 4.22 B | Canada |
 |
Viatris
VTRS
|
0.05 | $ 13.33 | -0.86 % | $ 16 B | USA |
 |
Jupiter Wellness
JUPW
|
-17 | - | - | $ 33.6 M | USA |
 |
Lannett Company
LCI
|
-5.74 | - | 1.15 % | $ 7.11 M | USA |
 |
Neoleukin Therapeutics
NLTX
|
-4.24 | - | - | $ 193 M | Canada |
 |
OptiNose
OPTN
|
-0.32 | - | - | $ 1.08 B | USA |
 |
PetIQ
PETQ
|
0.07 | - | 1.64 % | $ 400 M | USA |
 |
PLx Pharma
PLXP
|
-2.06 | - | -27.8 % | $ 2.56 M | USA |
 |
ProPhase Labs
PRPH
|
1.17 | - | - | $ 5.07 M | USA |
 |
Radius Health
RDUS
|
-1.49 | - | - | $ 1.42 B | USA |
 |
Recro Pharma
REPH
|
-0.14 | - | -4.76 % | $ 65.3 M | USA |
 |
cbdMD
YCBD
|
-1.79 | $ 0.75 | 0.39 % | $ 3.23 M | USA |
 |
Zomedica Corp.
ZOM
|
-0.08 | - | -0.21 % | $ 98 M | USA |
 |
Zynerba Pharmaceuticals
ZYNE
|
-0.82 | - | - | $ 55.5 M | USA |
 |
Tricida
TCDA
|
-3.44 | - | - | $ 3.25 M | USA |
 |
China Pharma Holdings
CPHI
|
-0.74 | $ 0.66 | 5.06 % | $ 2.83 M |  China |
 |
TherapeuticsMD
TXMD
|
-0.05 | $ 2.05 | 2.51 % | $ 23.7 M | USA |